MDGL

473.79

1.50% -7.21

Handel nachbörslich: 473.79

Madrigal Pharmaceuticals Inc (MDGL)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt MDGL? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$481.00

Offen:

$483.9

24-Stunden-Volumen:

256.38K

Relative Volume:

0.79

Marktkapitalisierung:

$10.76B

Einnahmen:

Nettoeinkommen (Verlust:

$-518.67M

KGV:

-18.86

EPS:

-25.12

Netto-Cashflow:

$-438.32M

1W Leistung:

+2.24%

1M Leistung:

-7.20%

6M Leistung:

+31.97%

1J Leistung:

+39.28%

1-Tages-Spanne:

$468.08

$484.25

1-Wochen-Bereich:

$463.53

$499.55

52-Wochen-Spanne:

$265.00

$615.00

Madrigal Pharmaceuticals Inc Stock (MDGL) Company Profile

Firmenname

Madrigal Pharmaceuticals Inc

Sektor

Healthcare (1112)

Branche

Biotechnology (621)

Telefon

404-380-9263

Adresse

200 BARR HARBOR DRIVE, SUITE 400, WEST CONSHOHOCKEN, PA

Mitarbeiter

528

Twitter

@MadrigalPharma

Nächster Verdiensttermin

2024-10-31

Neueste SEC-Einreichungen

MDGL's Discussions on Twitter

Compare MDGL vs VRTX, REGN, ARGX, ALNY, ONC

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
MDGL Madrigal Pharmaceuticals Inc	473.79	10.92B	0	-518.67M	-438.32M	-25.12
VRTX Vertex Pharmaceuticals Inc	465.02	117.03B	11.74B	3.68B	3.34B	14.19
REGN Regeneron Pharmaceuticals Inc	783.65	82.35B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	833.54	51.64B	3.06B	1.28B	447.35M	19.67
ALNY Alnylam Pharmaceuticals Inc	308.48	42.58B	3.21B	43.57M	221.36M	0.2405
ONC Beone Medicines Ltd Adr	346.42	38.87B	4.98B	69.60M	525.67M	0.5198

Madrigal Pharmaceuticals Inc Stock (MDGL) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2026-01-28	Eingeleitet	Barclays	Overweight
2026-01-06	Herabstufung	Wolfe Research	Outperform → Peer Perform
2025-11-05	Hochstufung	Cantor Fitzgerald	Neutral → Overweight
2025-11-03	Hochstufung	BofA Securities	Underperform → Neutral
2025-10-15	Eingeleitet	Truist	Buy
2025-09-04	Fortgesetzt	H.C. Wainwright	Buy
2025-02-28	Hochstufung	B. Riley Securities	Neutral → Buy
2025-02-27	Bestätigt	H.C. Wainwright	Buy
2024-06-28	Eingeleitet	Cantor Fitzgerald	Neutral
2024-06-11	Eingeleitet	Wolfe Research	Outperform
2024-04-22	Eingeleitet	BofA Securities	Underperform
2024-03-15	Hochstufung	B. Riley Securities	Sell → Neutral
2024-03-06	Eingeleitet	Citigroup	Buy
2024-02-26	Herabstufung	B. Riley Securities	Neutral → Sell
2022-12-20	Bestätigt	Oppenheimer	Outperform
2022-12-19	Bestätigt	H.C. Wainwright	Buy
2022-12-19	Bestätigt	Piper Sandler	Overweight
2022-12-19	Hochstufung	Raymond James	Underperform → Mkt Perform
2022-07-08	Herabstufung	B. Riley Securities	Buy → Neutral
2021-10-07	Eingeleitet	Jefferies	Buy
2021-08-06	Hochstufung	BMO Capital Markets	Market Perform → Outperform
2021-05-20	Fortgesetzt	Goldman	Buy
2020-11-24	Fortgesetzt	Evercore ISI	Outperform
2020-11-06	Bestätigt	H.C. Wainwright	Buy
2020-07-31	Eingeleitet	Piper Sandler	Overweight
2020-06-05	Eingeleitet	BMO Capital Markets	Market Perform
2020-05-05	Eingeleitet	Chardan Capital Markets	Buy
2020-01-30	Eingeleitet	Canaccord Genuity	Buy
2020-01-09	Hochstufung	UBS	Neutral → Buy
2019-11-07	Bestätigt	H.C. Wainwright	Buy
2019-06-25	Eingeleitet	Stifel	Hold
2019-06-10	Hochstufung	B. Riley FBR	Neutral → Buy
2019-02-28	Bestätigt	H.C. Wainwright	Buy
2019-02-22	Eingeleitet	SVB Leerink	Outperform
2019-01-23	Eingeleitet	UBS	Neutral
2018-12-14	Eingeleitet	Wolfe Research	Outperform
2018-12-12	Eingeleitet	B. Riley FBR	Neutral
2018-11-19	Herabstufung	Raymond James	Mkt Perform → Underperform
2018-11-16	Hochstufung	Evercore ISI	In-line → Outperform
2018-09-04	Eingeleitet	Citigroup	Buy
2018-08-06	Herabstufung	Goldman	Buy → Neutral
2018-06-28	Eingeleitet	Raymond James	Mkt Perform

Alle ansehen

Madrigal Pharmaceuticals Inc Aktie (MDGL) Neueste Nachrichten

11:50 AM

MDGL Strengthens MASH Franchise With New Genetic Approaches - Finviz

11:50 AM

10:00 AM

Madrigal (MDGL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release - Yahoo Finance

10:00 AM

07:48 AM

Madrigal inks licensing deal with China’s Suzhou Ribo for MASH drugs - MSN

07:48 AM

05:27 AM

Madrigal expands its MASH pipeline via Ribo deal - The Pharma Letter

05:27 AM

Feb 11, 2026

Madrigal expands MASH pipeline with siRNA therapies in $4.4 B deal - BioSpectrum Asia

Feb 11, 2026

Suzhou Ribo Life Science Signs Global siRNA Licensing Deal With Madrigal Pharma; Shares Rise 7% - marketscreener.com

Feb 11, 2026

Is Madrigal Pharmaceuticals Inc. in a long term uptrendJuly 2025 Retail & Trade Opportunity Analysis Reports - mfd.ru

Feb 11, 2026

Madrigal Continues Building Out MASH Pipeline With Ribo Life Science Deal - Citeline News & Insights

Feb 11, 2026

Ribo and Ribocure Announce Exclusive Global Licensing Agreement with Madrigal for Novel siRNA Therapeutics Targeting MASH - Finviz

Feb 11, 2026

Madrigal expands its MASH pipeline with exclusive global licensing agreement for six preclinical siRNA programs - marketscreener.com

Feb 11, 2026

Madrigal, China's Suzhou Ribo sign license deal for liver-disease programs - marketscreener.com

Feb 11, 2026

Madrigal turns to RNAi drugs from China to bolster MASH pipeline - Yahoo Finance

Feb 11, 2026

Madrigal, Suzhou Ribo in license deal for liver-disease programs - marketscreener.com

Feb 11, 2026

Madrigal Doubles Down On MASH With A $4.4 Billion Licensing Deal With China’s Ribo - Stocktwits

Feb 11, 2026

Madrigal Pharmaceuticals (MDGL) Secures Global License for siRNA Programs - GuruFocus

Feb 11, 2026

Madrigal Pharmaceuticals, Inc. announced an exclusive global licensing agreement to introduce six preclinical-stage siRNA (small interfering RNA) programs, aiming to significantly expand its research and development pipeline for metabolic dysfunction-asso - bitget.com

Feb 11, 2026

Madrigal Pharmaceuticals Expands MASH Pipeline with Exclusive License for siRNA Programs - Quiver Quantitative

Feb 11, 2026

Madrigal Expands its MASH Pipeline with Exclusive Global Licensing Agreement for Six Preclinical siRNA Programs - GlobeNewswire

Feb 11, 2026